Pharmaceutical

Five things for pharma marketers to know: Tuesday, June 27, 2017

Five things for pharma marketers to know: Tuesday, June 27, 2017

Merck announces positive trial results for CETP inhibitor; Purdue Pharma defends withholding of OxyContin marketing material; Roche's experimental haemophilia drug significantly cuts bleed rate

Five things for pharma marketers to know: Tuesday, June 20, 2017

Five things for pharma marketers to know: Tuesday, June 20, 2017

Novartis reports positive Phase-III results for Eylea competitor; AZ faces "critical transition point" in MYSTIC trial; physician shortage expected to rise

Five things for pharma marketers to know: Monday, June 19, 2017

Five things for pharma marketers to know: Monday, June 19, 2017

Adamis receives FDA approval for EpiPen rival Symjepi; Clovis reports positive trial results for ovarian cancer drug Rubraca; hedge fund billionaire John Paulson joins Valeant board of directors

Half of clinical-trial sites offer free transportation to patients

Half of clinical-trial sites offer free transportation to patients

Consent forms and reimbursement are the main deterrents of offering the service.

Five things for pharma marketers to know: Monday, June 12, 2017

Five things for pharma marketers to know: Monday, June 12, 2017

Teva gets FDA approval for Truvada generic; the FDA rejects Coherus' Neulasta biosimilar; only 17% of Americans find health industries to be innovative

Five things for pharma marketers to know: Monday, May 22, 2017

Five things for pharma marketers to know: Monday, May 22, 2017

Amgen's osteoporosis drug set back by safety issue; new FDA digital biz to hire 13 engineers; Celgene's MS drug bests Avonex in trial

Five things for pharma marketers to know: Thursday, May 11, 2017

Five things for pharma marketers to know: Thursday, May 11, 2017

FDA approves Merck/Lilly combo for lung cancer; new PhRMA requirements result in expulsion of 22 members; Pfizer to pay Sangamo $7 million for gene therapy programs

Five things for pharma marketers to know: Wednesday, April 26, 2017

Five things for pharma marketers to know: Wednesday, April 26, 2017

GSK warns Advair generic competition may affect business in 2017; Lilly plans to meet FDA about baricitinib; FDA warns companies selling 'illegal' products

Five things for pharma marketers to know: Monday, April 24, 2017

Five things for pharma marketers to know: Monday, April 24, 2017

QuintilesIMS partners with Salesforce; the E.U. to decide on new EMA location by June; drugmakers boost lobbying dollars in Q1

Five things for pharma marketers to know: Monday, April 10, 2017

Five things for pharma marketers to know: Monday, April 10, 2017

Gilead receives approval to market Harvoni, Sovaldi to adolescents; OncoMed ends mid-stage trials for pancreatic cancer drug; researchers use facial recognition software to diagnose